Midostaurin in Treating Older Patients With Mutated Acute Myeloid Leukemia Post-Transplant

Summary

This phase 2 trial studies the side effects and how well midostaurin works in treating older patients with acute myeloid leukemia with change in genetic material post-hematopoietic cell transplantation. Midostaruin may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving midostaruin post-transplant may improve patient outcomes.

Timeline

Start

—

Primary completion

2018-04

Completion

2018-04

Drugs

Indications